Armando Bartolazzi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1350859/publications.pdf

Version: 2024-02-01

107 papers 4,510 citations

32 h-index 64 g-index

107 all docs

107 docs citations

107 times ranked

5043 citing authors

#	Article	lF	CITATIONS
1	Imaging atherosclerotic plaques by targeting Galectin-3 and activated macrophages using (⁸⁹ Zr)-DFO- Galectin3-F(ab') ₂ mAb. Theranostics, 2021, 11, 1864-1876.	10.0	16
2	Transparency in Negotiation of European Union With Big Pharma on COVID-19 Vaccines. Frontiers in Public Health, 2021, 9, 647955.	2.7	12
3	TP53 drives abscopal effect by secretion of senescence-associated molecular signals in non-small cell lung cancer. Journal of Experimental and Clinical Cancer Research, 2021, 40, 89.	8.6	18
4	In Vivo Imaging of Thyroid Cancer with 99mTc-TR1401 and 99mTc-TR1402: A Comparison Study in Dogs. Journal of Clinical Medicine, 2021, 10, 1878.	2.4	3
5	AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity. Nature, 2021, 592, 799-803.	27.8	78
6	Effective rational humanization of a PASylated anti-galectin-3 Fab for the sensitive PET imaging of thyroid cancer in vivo. Scientific Reports, 2021, 11, 7358.	3.3	5
7	A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors. Oncogene, 2021, 40, 6143-6152.	5.9	16
8	Development of a Chimeric Antigen-Binding Fragment Directed Against Human Galectin-3 and Validation as an Immuno-Positron Emission Tomography Tracer for the Sensitive <i>In Vivo</i> In VivoOf Thyroid Cancer. Thyroid, 2020, 30, 1314-1326.	4.5	11
9	Remission of Kimura Disease With Carotid Hypervascularization After Cyclosporine Treatment. Dermatology Practical and Conceptual, 2020, 10, e2020030.	0.9	2
10	Scientific leadership: the Italian Government's perspective. Lancet, The, 2019, 394, 562-563.	13.7	0
11	Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs. International Journal of Molecular Sciences, 2019, 20, 1607.	4.1	40
12	A "seasonal bromoderma―in a farmer. Dermatologic Therapy, 2019, 32, e12764.	1.7	1
13	Galectin-3 Targeting in Thyroid Orthotopic Tumors Opens New Ways to Characterize Thyroid Cancer. Journal of Nuclear Medicine, 2019, 60, 770-776.	5.0	16
14	25-Hydroxyvitamin D serum levels and melanoma risk: a case–control study and evidence synthesis of clinical epidemiological studies. European Journal of Cancer Prevention, 2019, 28, 203-211.	1.3	22
15	Mice with reduced expression of the telomereâ€associated protein Ft1 develop p53â€sensitive progeroid traits. Aging Cell, 2018, 17, e12730.	6.7	24
16	Galectin-3 is essential for proper bone cell differentiation and activity, bone remodeling and biomechanical competence in mice. Metabolism: Clinical and Experimental, 2018, 83, 149-158.	3.4	27
17	Case report: skin injury after contact with a red spine starfish, <i>Protoreaster lincki</i> Dermatitis, 2018, 78, 95-96.	1.4	2
18	Optimizing the identification of riskâ€relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families. Cancer Medicine, 2018, 7, 46-55.	2.8	28

#	Article	IF	Citations
19	Loss of miR-204 expression is a key event in melanoma. Molecular Cancer, 2018, 17, 71.	19.2	25
20	Galectins in Cancer and Translational Medicine: From Bench to Bedside. International Journal of Molecular Sciences, 2018, 19, 2934.	4.1	13
21	Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma. Journal of Experimental and Clinical Cancer Research, 2018, 37, 318.	8.6	66
22	The management of pseudomyogenic hemangioendothelioma of the foot: A case report and review of the literature. Dermatologic Therapy, 2018, 31, e12725.	1.7	12
23	MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors. Cell Death and Disease, 2018, 9, 895.	6.3	35
24	Galectin-3: The Impact on the Clinical Management of Patients with Thyroid Nodules and Future Perspectives. International Journal of Molecular Sciences, 2018, 19, 445.	4.1	22
25	Antiproliferative Effects of $1\hat{1}\pm$ -OH-vitD3 in Malignant Melanoma: Potential Therapeutic implications. Scientific Reports, 2017, 7, 40370.	3.3	20
26	Comparative analysis of diagnostic performance, feasibility and cost of different test-methods for thyroid nodules with indeterminate cytology. Oncotarget, 2017, 8, 49421-49442.	1.8	45
27	Diffuse Follicular Variant of Papillary Thyroid Carcinoma: A Case Report with a Revision of Literature. Rare Tumors, 2016, 8, 159-161.	0.6	3
28	A Case of Sinonasal Melanoma With Unusual Primary Exon 17 KIT D820G Mutation. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, e94-e97.	1.2	1
29	Noninvasive <i>In Vivo</i> Imaging and Biologic Characterization of Thyroid Tumors by ImmunoPET Targeting of Galectin-3. Cancer Research, 2016, 76, 3583-3592.	0.9	22
30	Oncocytic Variant of Medullary Thyroid Carcinoma: A Rare Case of Sporadic Multifocal and Bilateral <i>RET</i> Wild-Type Neoplasm with Revision of the Literature. Rare Tumors, 2016, 8, 166-168.	0.6	6
31	Combined clinical and ultrasound follow-up assists in malignancy detection in Galectin-3 negative Thy-3 thyroid nodules. Endocrine, 2016, 54, 139-147.	2.3	10
32	Investigation of VOCs associated with different characteristics of breast cancer cells. Scientific Reports, 2015, 5, 13246.	3.3	60
33	Nodular Lymphocyte-Predominant Hodgkin Lymphoma in a Warthin Tumor of the Parotid Gland. International Journal of Surgical Pathology, 2015, 23, 419-423.	0.8	14
34	HIPK2 deficiency causes chromosomal instability by cytokinesis failure and increases tumorigenicity. Oncotarget, 2015, 6, 10320-10334.	1.8	30
35	Diagnostic Value of Minor Salivary Glands Biopsy in Systemic Amyloidosis. Blood, 2015, 126, 5381-5381.	1.4	2
36	Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors. Cell Death and Disease, 2014, 5, e1100-e1100.	6.3	18

#	Article	IF	Citations
37	Schwannoma-Like Pleomorphic Adenoma: A Case Report with Review of the Literature. Head and Neck Pathology, 2014, 8, 178-181.	2.6	10
38	Discovery of chemotherapy-associated ovarian cancer antigens by interrogating memory T cells. International Journal of Cancer, 2014, 134, 1823-1834.	5.1	19
39	Homeodomainâ€interacting protein kinase2 in human idiopathic pulmonary fibrosis. Journal of Cellular Physiology, 2013, 228, 235-241.	4.1	26
40	A Very Unusual Thyroid Tumor: A Nodule with Mature Fat Papillary Hyperplasia and Focal Atypia. Rare Tumors, 2013, 5, 165-166.	0.6	3
41	Primary Thyroid Paraganglioma: A Rare Entity Affecting Middle-aged Women. American Surgeon, 2013, 79, 351-353.	0.8	3
42	Methodology and Technical Requirements of the Galectin-3 Test for the Preoperative Characterization of Thyroid Nodules. Applied Immunohistochemistry and Molecular Morphology, 2012, 20, 2-7.	1.2	19
43	HIPK2 Controls Cytokinesis and Prevents Tetraploidization by Phosphorylating Histone H2B at the Midbody. Molecular Cell, 2012, 47, 87-98.	9.7	58
44	Galectin-3 Impairment of MYCN-Dependent Apoptosis-Sensitive Phenotype Is Antagonized by Nutlin-3 in Neuroblastoma Cells. PLoS ONE, 2012, 7, e49139.	2.5	22
45	Renal cell carcinoma diagnosed by cutaneous metastasis: a case report. Cutis, 2012, 90, 196-9.	0.3	4
46	Hyperbaric oxygen therapy in a case of cholesterol crystal embolization. American Journal of Emergency Medicine, 2011, 29, 694.e3-694.e6.	1.6	3
47	Efficacy of acitretin in the treatment of squamous cell carcinoma of the oral cavity. European Journal of Cancer Prevention, 2011, 20, 429-430.	1.3	1
48	HIPK2 phosphorylates \hat{l} "Np63 \hat{l} ± and promotes its degradation in response to DNA damage. Oncogene, 2011, 30, 4802-4813.	5.9	57
49	Monitoring of melanoma released volatile compounds by a gas sensors array: From in vitro to in vivo experiments. Sensors and Actuators B: Chemical, 2011, 154, 288-294.	7.8	20
50	MYCN Sensitizes Human Neuroblastoma to Apoptosis by HIPK2 Activation through a DNA Damage Response. Molecular Cancer Research, 2011, 9, 67-77.	3.4	30
51	A primary cutaneous adenoid-cystic carcinoma in a young woman. Differential diagnosis and clinical implications. Rare Tumors, 2011, 3, 7-9.	0.6	19
52	The Loss of the p53 Activator HIPK2 Is Responsible for Galectin-3 Overexpression in Well Differentiated Thyroid Carcinomas. PLoS ONE, 2011, 6, e20665.	2.5	54
53	A sensor array and GC study about VOCs and cancer cells. Sensors and Actuators B: Chemical, 2010, 146, 483-488.	7.8	31
54	Galectin-3 detection on large-needle aspiration biopsy improves preoperative selection of thyroid nodules: A prospective cohort study. Annals of Medicine, 2010, 42, 70-78.	3.8	22

#	Article	IF	Citations
55	Primary cutaneous Hodgkin lymphoma. Journal of the American Academy of Dermatology, 2010, 63, e52-e53.	1.2	17
56	<i>Galâ€3</i> is stimulated by gainâ€ofâ€function <i>p53</i> mutations and modulates chemoresistance in anaplastic thyroid carcinomas. Journal of Pathology, 2009, 218, 66-75.	4. 5	33
57	HIPK2 is involved in cell proliferation and its suppression promotes growth arrest independently of DNA damage. Cell Proliferation, 2009, 42, 373-384.	5. 3	33
58	Melanoma Volatile Fingerprint with a Gas Sensor Array: In Vivo and In Vitro Study. Procedia Chemistry, 2009, 1, 995-998.	0.7	6
59	Rectal and gynecologic amputation for a giant eccrine porocarcinoma of the pelvic floor. American Surgeon, 2009, 75, 269-72.	0.8	0
60	Receptors for the liver synthesized growth factors IGFâ€1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. Acta Ophthalmologica, 2008, 86, 20-25.	1.1	33
61	Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncology, The, 2008, 9, 543-549.	10.7	284
62	Thyroid Cancer Imaging In Vivo by Targeting the Anti-Apoptotic Molecule Galectin-3. PLoS ONE, 2008, 3, e3768.	2.5	33
63	Angiomatoid lesions revealing an atrial myxoma. European Journal of Dermatology, 2008, 18, 203-4.	0.6	0
64	Actinic Reticulosis with clonal TCR (T-cell receptor) gene rearrangement. European Journal of Dermatology, 2008, 18, 598-600.	0.6	3
65	Melanoma mimicry on a tattoo: An autograft hypothesis. Journal of the American Academy of Dermatology, 2007, 57, S122-S123.	1.2	12
66	Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology, 2006, 48, 212-213.	2.9	17
67	Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology. British Journal of Cancer, 2006, 95, 204-209.	6.4	52
68	Repression of the Antiapoptotic Molecule Galectin-3 by Homeodomain-Interacting Protein Kinase 2-Activated p53 Is Required for p53-Induced Apoptosis. Molecular and Cellular Biology, 2006, 26, 4746-4757.	2.3	93
69	The Rare Condition of Maxillary Osteomyelitis. Journal of Craniofacial Surgery, 2005, 16, 861-864.	0.7	5
70	Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Modern Pathology, 2005, 18, 541-546.	5 . 5	131
71	Receptors for the Liver Synthesized Growth Factors IGF-1 and HGF/SF in Uveal Melanoma: Intercorrelation and Prognostic Implications., 2005, 46, 4372.		68
72	Thyroid Fine Needle Aspiration Cytology. , 2004, , 430-441.		0

#	Article	IF	Citations
73	Cyclolignans as Inhibitors of the Insulin-Like Growth Factor-1 Receptor and Malignant Cell Growth. Cancer Research, 2004, 64, 236-242.	0.9	334
74	Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 183-8.	2.8	48
75	Detection and molecular characterisation of thyroid cancer precursor lesions in a specific subset of Hashimoto's thyroiditis. British Journal of Cancer, 2004, 91, 1096-1104.	6.4	41
76	From the bench to the bedside. Galectin-3 immunodetection for improving the preoperative diagnosis of the follicular thyroid nodules. Biomedicine and Pharmacotherapy, 2004, 58, 356-359.	5.6	24
77	Methodological Considerations Regarding the Use of Galectin-3 Expression Analysis in Preoperative Evaluation of Thyroid Nodules. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 950-950.	3.6	22
78	CD44s adhesive function spontaneous and PMA-inducible CD44 cleavage are regulated at post-translational level in cells of melanocytic lineage. Melanoma Research, 2003, 13, 325-337.	1.2	42
79	Pivotal Role of KARAP/DAP12 Adaptor Molecule in the Natural Killer Cell–mediated Resistance to Murine Cytomegalovirus Infection. Journal of Experimental Medicine, 2002, 195, 825-834.	8.5	101
80	A Novel Type of SYT/SSX Fusion: Methodological and Biological Implications. Modern Pathology, 2002, 15, 679-685.	5.5	30
81	Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Investigative Ophthalmology and Visual Science, 2002, 43, 1-8.	3.3	209
82	SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: a gain of function of the $t(X;18)(p11.2;q11.2)$ translocation. Cancer Research, 2002, 62, 3861-7.	0.9	49
83	Cloning and characterization of spliced fusion transcript variants of synovial sarcoma: SYT/SSX4, SYT/SSX4v, and SYT/SSX2v. Possible regulatory role of the fusion gene product in wild type SYT expression. Gene, 2001, 268, 173-182.	2.2	49
84	Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet, The, 2001, 357, 1644-1650.	13.7	379
85	RESPONSE: Re: A Novel Fusion Gene, SYT-SSX4, in Synovial Sarcoma. Journal of the National Cancer Institute, 2001, 93, 1348-1349.	6.3	1
86	Seminoma with cutaneous metastases in a dog. Journal of the American Animal Hospital Association, 2000, 36, 253-256.	1.1	22
87	Overexpression of p53 and bcl-2 proteins and the presence of HPV infection are independent events in head and neck cancer. Journal of Oral Pathology and Medicine, 2000, 29, 173-179.	2.7	22
88	Brachial plexus neuropathy as unusual onset of diffuse neurolymphomatosis. Neurological Sciences, 2000, 21, 241-245.	1.9	20
89	Thyroid disease classification. Lancet, The, 2000, 356, 2010.	13.7	7
90	Improving accuracy of cytology for nodular thyroid lesions. Lancet, The, 2000, 355, 1661-1662.	13.7	37

#	Article	IF	CITATIONS
91	Galectin-3 and CD44v6 Isoforms in the Preoperative Evaluation of Thyroid Nodules. Journal of Clinical Oncology, 1999, 17, 3494-3502.	1.6	140
92	Structural Variability of CD44v Molecules and Reliability of Immunodetection of CD44 Isoforms Using mAbs Specific for CD44 Variant Exon Products. American Journal of Pathology, 1999, 154, 291-300.	3.8	34
93	Glycosylation of CD44 is implicated in CD44-mediated cell adhesion to hyaluronan Journal of Cell Biology, 1996, 132, 1199-1208.	5.2	166
94	Expression of $\hat{l}\pm3\hat{l}^21$ integrin receptor and its ligands in human lung tumors. International Journal of Cancer, 1995, 64, 248-252.	5.1	30
95	Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons Journal of Cell Biology, 1995, 131, 1623-1633.	5.2	141
96	Murine monoclonal antibody elicited with antibiotic-exposed Escherichia coli exerts protective capacity in experimental bacterial infections. Journal of Medical Microbiology, 1994, 41, 179-183.	1.8	4
97	Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development Journal of Experimental Medicine, 1994, 180, 53-66.	8.5	321
98	Transformation and tumor progression are frequently associated with expression of the $\hat{l}\pm 3/\hat{l}^21$ heterodimer in solid tumors. International Journal of Cancer, 1994, 58, 488-491.	5.1	39
99	Integrin expression in cutaneous malignant melanoma: Association of the $\hat{l}\pm 3/\hat{l}^21$ heterodimer with tumor progression. International Journal of Cancer, 1993, 54, 68-72.	5.1	113
100	Differential Effect of Human and Murine Polyclonal and Monoclonal Antisera on TNF-α Production by Human Monocytes. Journal of Chemotherapy, 1993, 5, 317-324.	1.5	1
101	Immunocytodiagnosis of atypical hyperplasia and endometrial carcinoma in post-menopausal women. International Journal of Cancer, 1992, 51, 869-872.	5.1	3
102	Monoclonal antibodies to glutathione S-Transferase π–immunohistochemical analysis of human tissues and cancers. International Journal of Cancer, 1991, 47, 193-201.	5.1	59
103	Use of monoclonal antibodies in solid tumors diagnosis-the endometrial carcinoma. Cytotechnology, 1991, 5, 35-40.	1.6	0
104	Monoclonal Antibodies to a Soluble Metallic Radioisotope Chelator: Development and Characterization. Hybridoma, 1991, 10, 695-705.	0.6	7
105	Generation and Characterization of the Murine Monoclonal Antibody M-KID 2 to VLA-3 Integrin. Hybridoma, 1991, 10, 707-720.	0.6	23
106	Expression and production of tenascin in benign and malignant lesions of melanocyte lineage. International Journal of Cancer, 1990, 46, 586-590.	5.1	46
107	The dilemma of indeterminate thyroid cytology: how many markers are needed for a reliable diagnosis?. Annals of Thyroid, 0, 3, 17-17.	1.0	0